Company
At a Glance
Team
Scientific Advisory Board
Videos & Publications
Capabilities & Compliance
News & Events
Join the Team
Diagnostics
Introduction
Immunoscore® in Localized Colon Cancer
Immunoscore® IC in Lung Cancer
Pharma Services
Immunogram
Our offer within the TME
Immunoscore® CR
Immunosign®
IO Sequencing
Biostats
On demand Assays
The Cancer Immune Atlas
Assay Development Services
Immunoscore®
Immunoscore®
IMMUNOSCORE®
Scoring Immune Response in Colon Cancer
For unmatched clinical performance in routine settings
More info
IMMUNOSCORE® IC
in Non-Small Cell Lung cancer (NSCLC)
Combine PD-L1 with CD8 to improve predictive value of PD-L1
More info
Clinical Research
A new class of Immuno-Oncology Scoring Services
For academic, clinical centers and biopharmaceutical companies
More info
Companion Diagnostic
HalioDx approach to successfully develop CDx
From Biomarker Discovery to CDx development and commercialization
More info
Previous
Next
Latest News
& Events
Immunoscore® to support Immuno-oncology and microbiome research within the ONCOBIOME consortium
Read more
Jérôme Galon received the European Inventor Award 2019 for Immunoscore®
Read more
BIO Europe
Date:
From 2019-11-11 to 2019-11-13
Location:
Hamburg
Read more
ESMO Asia
Date:
From 2019-11-22 to 2019-11-24
Location:
Singapore
Read more
See all news
See all events
In the media :
Tuesday 04 June 2019
-
MyPharma Editions:
HalioDx : Immunoscore® démontre son utilité clinique dans le cancer du colon de stade III
|
Wednesday 20 March 2019
-
Spoke:
Transgene: A Positive 2018, Moving Ahead with a Strong Portfolio | Spoke
|
Thursday 14 March 2019
-
MyPharma Editions:
Transgene : le développement de myvac™ bénéficie d’une aide de 5,2 millions d’euros du Programme d’Investissements d’Avenir
|
Wednesday 13 March 2019
-
Spoke:
Transgene - NEOVIVA Project Supporting the Development of myvac™ Awarded a €5.2 Million Grant from Bpifrance’s “Investments for the Future” Programme | Spoke
|
Wednesday 14 November 2018
-
Marseille Immunopole:
RT @HalioDx: #Immunoscore Provides Risk Assessments for All Stages of #ColonCancer https://t.co/DjPKMRk2yY @TargetedOnc @JeromeGalon @sitcancer #SitC2018 https://t.co/Jag3zAcAS9
|